Recent 8-K filings for PBSV
Highest-materiality recent filing
Pharma-Bio Serv FY2024 rev $9.5M (-$7.5M YoY), net loss $0.8M; declares $0.075 special dividend
- Revenue for year ended Oct 31, 2024 approximately $9.5M, a decrease of $7.5M from prior year.
- Net loss of approximately $0.8M compared to net income of $1.3M in the prior year.
-
Pharma-Bio Serv FY2024 rev $9.5M (-$7.5M YoY), net loss $0.8M; declares $0.075 special dividend
Revenue for year ended Oct 31, 2024 approximately $9.5M, a decrease of $7.5M from prior year.
-
Pharma-Bio Serv Q3 revenue falls to $2.4M, swings to net loss of $0.3M
Q3 revenue $2.4M, down ~$2.2M (48%) from $4.6M in same quarter last year.
-
Pharma-Bio Serv Q2 revenue down 48% to $2.4M; net loss $0.2M vs income $0.4M
Q2 revenue $2.4M, decline of $2.2M from $4.6M in prior-year quarter.
-
Pharma-Bio Serv Q1 revenue down 44% to $2.4M; swings to net loss of $270.7K
Revenue for Q1 ended Jan 31, 2024: $2.4M, down $1.9M from $4.3M in prior-year quarter.
-
Revenue of $17.0M, down $2.4M YoY; net income of $1.3M, up $0.3M YoY.
-
Pharma-Bio Serv declares special dividend of $0.075 per share, payable Feb 15, 2024
Board approved a special dividend of $0.075 per share.
-
Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M
Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event earnings